Streetbeat News

Regulatory

ETHUSD

MATICUSD

A trader on Polymarket lost $72,000 after betting on Trump's victory in the upcoming presidential elections. Trump's odds fell 12% after Kamala Harris replaced Biden as the Democratic nominee. Polymarket, built on Ethereum's Layer-2 chain Polygon, has become a leading prediction market for U.S. elections.

Portfolio Pulse from Aniket Verma

July 31, 2024 | 1:39 am

FHN

First Horizon's 2024 capital stress test results show a strong resilience with a CET1 ratio of 9.5%, which is 500 basis points above the regulatory minimum. This reflects the company's diversified loan portfolio and strong risk culture.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 8:59 pm

COP

CVX

EOG

IYE

MRO

USO

VDE

XLE

XOM

Tensions in Venezuela rise as opposition disputes election results, impacting oil ETFs. Major oil companies and ETFs saw gains, except for the United States Oil Fund (USO), which traded lower.

Portfolio Pulse from Anthony Noto

July 30, 2024 | 8:58 pm

VST

Vistra shares are trading higher after the company announced that the Nuclear Regulatory Commission has approved its request to extend the operation of Comanche Peak Nuclear Power Plant through 2053.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 8:49 pm

VST

Vistra has received approval from the NRC to operate the Comanche Peak Nuclear Plant through 2053. The 2,400-megawatt plant will continue to provide reliable, zero-carbon electricity.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 8:49 pm

FGEN

Trading halt status for FibroGen Inc. (FGEN) was updated at 4:30 PM ET. The article provides information on the news and resumption times.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 8:30 pm

TECX

Tectonic Therapeutic, Inc. (NASDAQ: TECX) has received FDA clearance for its Investigational New Drug (IND) application for TX45, an Fc-relaxin fusion protein aimed at treating Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The company plans to initiate a global Phase 2 clinical trial in Q3 2024, with topline results expected in 2026. Phase 1a results in healthy volunteers are expected this September, and Phase 1b results in mid-2025.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 8:22 pm

MGNX

MacroGenics provided an update on its Vobramitamab Duocarmazine (vobra duo) program, including the TAMARACK study. The study reached its primary endpoint, leading to the discontinuation of additional dosing for remaining participants. The company plans to present data at the ESMO Congress 2024 and expects to have mature efficacy findings later in the year.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 8:20 pm

GBTC

Cryptocurrency markets are down, with Bitcoin, Ethereum, and Dogecoin experiencing declines. Grayscale is introducing a new Bitcoin ETF. Despite the downturn, analysts suggest Bitcoin is on track for a September breakout. Notable developments include Russia greenlighting crypto for cross-border payments and the SEC amending its complaint against Binance.

Portfolio Pulse from Khyathi Dalal

July 30, 2024 | 8:13 pm

TSLA

Tesla shares are trading lower due to several recent announcements. CEO Elon Musk confirmed the cancellation of the Plaid+ variant of the Model S, with the high-performance niche to be filled by the Roadster in 2025. Additionally, Tesla is recalling 1.85 million vehicles in the U.S. due to a risk of unlatched hoods obstructing drivers' views. Despite an over-the-air update, the recall has negatively impacted market sentiment. Tesla's recent earnings report showed an EPS of 52 cents, missing estimates of 62 cents, but revenue of $25.500 billion exceeded forecasts of $24.726 billion.

Portfolio Pulse from Vaishali Prayag

July 30, 2024 | 8:09 pm